Drug Approval | March 04, 2023
Caplin Steriles gets USFDA approval for Rocuronium Bromide Injection
Rocuronium Bromide Injection is a neuromuscular blocking agent
Rocuronium Bromide Injection is a neuromuscular blocking agent
Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules
The company expects the GMP approval from Saudi Food and Drug Authority (SFDA) to soon pave the way for marketing authorizations from the largest market in the GCC region
Receives Subject Expert Committee recommendation to bring new therapies of Pompe, ASMD to India
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza Tablets, 2.5 mg and 5 mg market achieved annual sales of approximately US $122.3 million
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates
The Applied Biosystems TaqPath PCR kits have been analytically- and clinically-validated for use in patient care
Subscribe To Our Newsletter & Stay Updated
